Cambridge Healthtech Associates (CHA)™, a leading provider of consulting, consortia and communities in the life sciences industry, today announced the appointment of Dawn Van Dam as General Manager. The former University of Guelph executive will be responsible for overseeing the day-to-day operations of CHA.
"We are excited that Van Dam is joining the CHI management team," said Phillips Kuhl, President and CEO of Cambridge Healthtech Institute (CHI), the parent company of CHA. “Her 25+ years of experience in consulting, market research, social media and growing organizational sales and profitability in the life sciences industry will be a tremendous asset to the CHA organization."
“The life sciences industry, both pharmaceutical and biotech companies, and their suppliers, are challenged to produce new, novel therapeutic solutions faster and more efficiently than ever before. Cambridge Healthtech Associates is uniquely positioned to help organizations succeed in their discovery and pre-clinical development processes, with our strong team of experienced individuals. Our goal is to help the industry uncover the market insights, put together the key people to understand and accelerate product development and ensure that thought leaders are well aware of new and emerging solutions to advance the discovery phase,” said Van Dam.
Van Dam’s experience includes serving as Chief Marketing Officer for the University of Guelph, Laboratory Services in Ontario, Canada. Prior to that, Van Dam held various senior-level positions in the health care industry including 17 years in the pharmaceutical industry, and she graduated from The Wharton School at the University of Pennsylvania.
About Cambridge Healthtech Associates
Cambridge Healthtech Associates (CHA) uses its unique collaborative model to improve the speed, economics and effectiveness of pharmaceutical and biotech drug development, leveraging its consortia, consulting and communities to help clients in the life science industry achieve their individual goals.
Cambridge Healthtech Consortia™ bring together biopharmaceutical companies and life science vendors to evaluate and validate new technologies and service offerings in a pre-competitive environment, e.g. drug safety. This collaborative model empowers technology vendors and industry end user to assess a number of technologies in a cost-effective manner leading to better protocols.
Cambridge Healthtech Consulting™ helps clients do strategic planning, conduct market research, forecast market response and prepare business plans and models to accelerate product adoption. CHA’s collaborative model helps clients forge relationships with a wide range of constituents in the pharmaceutical and biotech industries.
Cambridge Healthtech Communities™ create and manage private online communities within several verticals in life sciences. The communities are designed to provide individuals in industry and academia with resources to share information, as well as offer unique peer-to-peer engagement opportunities on a range of valuable industry topics. The current Cambridge Healthtech Communities are NGS Leaders™, committed to advancing the use of next-generation sequencing, and the Drug Safety Executive Council™, which is focused on improving the drug pipeline.